158 related articles for article (PubMed ID: 9543008)
21. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
[TBL] [Abstract][Full Text] [Related]
22. Two hydrolase resistant analogues of diadenosine 5',5"'-P1,P3-triphosphate for studies with Fhit, the human fragile histidine triad protein.
Blackburn GM; Liu X; Rösler A; Brenner C
Nucleosides Nucleotides; 1998; 17(1-3):301-8. PubMed ID: 9708352
[TBL] [Abstract][Full Text] [Related]
23. In vitro inhibition of the enzymatic activity of tumor suppressor FHIT gene product by carcinogenic transition metals.
Kowara R; Karaczyn AA; Fivash MJ; Kasprzak KS
Chem Res Toxicol; 2002 Mar; 15(3):319-25. PubMed ID: 11896678
[TBL] [Abstract][Full Text] [Related]
24. The histidine triad superfamily of nucleotide-binding proteins.
Brenner C; Bieganowski P; Pace HC; Huebner K
J Cell Physiol; 1999 Nov; 181(2):179-87. PubMed ID: 10497298
[TBL] [Abstract][Full Text] [Related]
25. Fragile histidine triad gene and skin cancer.
Zanesi N; Croce CM
Eur J Dermatol; 2001; 11(5):401-4. PubMed ID: 11525944
[TBL] [Abstract][Full Text] [Related]
26. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
27. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
Ishii H; Dumon KR; Vecchione A; Fong LY; Baffa R; Huebner K; Croce CM
JAMA; 2001 Nov; 286(19):2441-9. PubMed ID: 11712940
[TBL] [Abstract][Full Text] [Related]
28. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
29. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
30. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells.
Wu R; Connolly DC; Dunn RL; Cho KR
J Natl Cancer Inst; 2000 Feb; 92(4):338-44. PubMed ID: 10675384
[TBL] [Abstract][Full Text] [Related]
31. Selective monitoring of the enzymatic activity of the tumor suppressor Fhit.
Hacker SM; Mortensen F; Scheffner M; Marx A
Angew Chem Int Ed Engl; 2014 Sep; 53(38):10247-50. PubMed ID: 25098403
[TBL] [Abstract][Full Text] [Related]
32. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region.
Glover TW; Hoge AW; Miller DE; Ascara-Wilke JE; Adam AN; Dagenais SL; Wilke CM; Dierick HA; Beer DG
Cancer Res; 1998 Aug; 58(15):3409-14. PubMed ID: 9699673
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
34. Control of 5',5'-dinucleoside triphosphate catabolism by APH1, a Saccharomyces cerevisiae analog of human FHIT.
Chen J; Brevet A; Blanquet S; Plateau P
J Bacteriol; 1998 May; 180(9):2345-9. PubMed ID: 9573184
[TBL] [Abstract][Full Text] [Related]
35. New interactions between tumor suppressor Fhit protein and a nonhydrolyzable analog of its A
Krakowiak A; Kocoń-Rębowska B; Dolot R; Piotrzkowska D
FEBS Lett; 2017 Feb; 591(3):548-559. PubMed ID: 28094435
[TBL] [Abstract][Full Text] [Related]
36. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
38. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.
Werner NS; Siprashvili Z; Fong LY; Marquitan G; Schröder JK; Bardenheuer W; Seeber S; Huebner K; Schütte J; Opalka B
Cancer Res; 2000 Jun; 60(11):2780-5. PubMed ID: 10850413
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
Guidi E; Uboldi C; Ferretti L
Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
[TBL] [Abstract][Full Text] [Related]
40. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
Wierzbicki PM; Adrych K; Kartanowicz D; Dobrowolski S; Stanislawowski M; Chybicki J; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():63-70. PubMed ID: 20083853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
